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Cellular microRNAs (miRNAs) are an important class of small, non-coding RNAs that bind to host mRNAs
based on sequence complementarity and regulate protein expression. They play important roles in controlling
key cellular processes including cellular inception, differentiation and death. While several viruses have been
shown to encode for viral miRNAs, controversy persists over the expression of a functional miRNA encoded in
the human immunodeficiency virus type 1 (HIV-1) genome. However, it has been reported that HIV-1
infectivity is influenced by cellular miRNAs. Either through directly targeting the viral genome or by targeting
host cellular proteins required for successful virus replication, multiple cellular miRNAs seem to modulate
HIV-1 infection and replication. Perhaps as a survival strategy, HIV-1 may modulate proteins in the miRNA
biogenesis pathway to subvert miRNA-induced antiviral effects. Global expression profiles of cellular miRNAs
have also identified alterations of specific miRNAs post-HIV-1 infection both in vitro and in vivo (in various
infected patient cohorts), suggesting potential roles for miRNAs in pathogenesis and disease progression.
However, little attention has been devoted in understanding the roles played by these miRNAs at a cellular
level. In this manuscript, we review past and current findings pertaining to the field of miRNA and HIV-1
interplay. In addition, we suggest strategies to exploit miRNAs therapeutically for curbing HIV-1 infectivity,
replication and latency since they hold an untapped potential that deserves further investigation.
© 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.Introduction
Human immunodeficiency virus type 1 (HIV-1), the
causative agent of the acquired immunodeficiency
syndrome (AIDS) pandemic, was discovered over
three decades ago. Extensive research paved the
way to the development of many anti-retroviral drugs
targeting a limited number of steps on the virus life
cycle, leading to combination anti-retroviral therapy
(cART), which today results in controlled viral replica-
tion inmany treated individuals. However, cART is not
able to eradicate the virus due to the existence of viral
reservoirs. In addition, these drugs are associated
with frequent development of toxicities and side
effects that may require changes in drug regimen
or stopping treatment altogether. Furthermore, the
continuous and perhaps increasing emergence of
drug-resistant HIV-1 strains in infected patients, toThe Authors. Published by Elsevier Ltd.
pen access under CC BY-NC-ND license.someextent relatedwith poor adherence to treatment,
poses a threat to the effectiveness of the current cART
regimens [1–3]. These compounding factors under-
score the need to find new targets and to develop
additional, complementary therapeutic approaches.
Recently, much attention has been drawn to research
pertaining to HIV–host interactions, in order to uncover
novel drug targets.
To initiate infection, the HIV-1 envelope glycopro-
tein gp120 present in the surface of virions binds to its
primary cellular receptor CD4, which is expressed on
several immune and non-immune cells including T
helper lymphocytes, macrophages, dendritic cells
(DCs) and brain-resident microglia. CD4 binding
triggers a conformational change that enables gp120
to bind to a co-receptor, mainly the G-protein-coupled
chemokine receptors CCR5 and/or CXCR4, and the
subsequent transmission of conformational alterationJ. Mol. Biol. (2014) 426, 1178–1197
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glycoprotein that will mediate the fusion of the viral
and cellular membranes and the release of the viral
core into the cytoplasm of the host cell. The viral entry
process has been suggested to determine the viral
tropism [4,5]. Post-entry, the viral capsid undergoes
rapid uncoating in the cytoplasmof infected cells while
the genomic single-stranded RNA undergoes reverse
transcription, forming a double-stranded cDNA that
represents the complete viral genome [6,7] and is
packedwith additional viral proteins such as integrase
to form the pre-integration complex (PIC). PICs are
then imported into the nucleus, where the viral DNA is
integrated into the host genome by integrase through
recognition of ATT-rich sites within the two long
terminal repeats (LTRs) in both ends of the viral
cDNA [8–10]. After integration, multiple factors such
as the integration site or the activation status of the cell
will determine whether the viral genome remains
latent [11,12] or is actively transcribed into viral
mRNAs, a process that is modulated via activation
of various host cellular transcription factors (including
NF-κB, AP-1, C/EBPs, SP-1, NFATs, etc.) that can
bind to multiple binding sites present in the viral LTR
[13–17]. The viral mRNAs, nowmasquerading as host
mRNAs, undergo the normal processing of host
mRNAs (5′ capping, polyadenylation, splicing) and
serve as templates for the synthesis of viral proteins in
a tightly regulated process. Finally, full-length viral
RNAs that will become the genomic RNA of the new
virions assemble with the Gag polyprotein (containing
the structural proteins) and the essential regulatory
proteins leading to the formation of new virions, which
will be released from the cellular membrane and
undergo maturation, in a viral protease-mediated
cleavage of Gag polyprotein that is required for
infectivity [18–21].
Since the virus has evolved to carry such minimal
machinery, it is not surprising that HIV-1 usurps a
multitude of host cellular proteins for efficient comple-
tion of its life cycle. Several RNA interference (RNAi)
screens have identified many host proteins—termed
“HIV Dependency Factors” (HDFs)—and cellular
pathways important for HIV-1 infection [22–30]. The
essentiality of certain HDFs during different stages of
the viral life cycle has been well studied. Thus, in
addition to targeting HIV-1 proteins, therapeutic
approaches directed toward HDFs have also become
a potential strategy to combat HIV-1. Indeed, inhibiting
these proteins by RNAi strategies such as small
interfering RNA (siRNA)-mediated knockdown has
been shown to affect HIV-1 replication, underscoring
the importance of the targeted HDFs [31–33].
Therefore, manipulating the expression of such host
proteins provides a novel avenue of reducing HIV-1
infectivity in otherwise susceptible cells.
Interestingly, eukaryotic cells possess endogenous
RNAi mechanisms that have only been uncovered
during the last two decades [34], with the so-calledmicroRNAs (miRNAs) being an important family of
small, non-coding RNAs (sncRNAs). Mammalian
miRNAs are temporally and spatially regulated
sncRNAs that are potent regulators of gene expres-
sion. In their mature form,miRNAs bind primarily to the
3′ untranslated region (UTR) of target mRNAs through
base pair complementarity, leading to silencing or
reduced protein levels either through translational
repression or through mRNA degradation [35–37].
Cellular miRNAs play fundamental roles during basic
cellular processes such as differentiation, develop-
ment and death. In addition, studies involving miRNAs
and their dysregulation have helped identify key
concepts in infectious diseases, cancer and both
generation and maintenance of adequate innate and
adaptive immune responses [38–43].
Understanding the role ofmiRNAs inHIV-1 infection
is an emerging area of interest. Few cellular miRNAs
have been shown to directly bind to the viral RNA and
inhibit HIV-1 replication. However, a growing number
of cellular miRNAs can indirectly affect HIV-1 infection
by targeting HDFs. As an ever-evolving strategy,
HIV-1 seems to be able not only to modulate cellular
miRNA profiles but also to interfere with the overall
biogenesis of miRNAs. However, whether or not
HIV-1 encodes viral miRNAs still remains a matter of
debate. The importance of miRNAs in HIV-1 infection
has been previously reviewed [44,45]. Here, we
provide an overview of the current literature charac-
terizing the complex interactions between HIV-1 and
miRNAs and provide insights into potential therapeu-
tic applications of miRNAs in the context of HIV-1
infection and eradication efforts.miRNA Biogenesis and Interference of
HIV-1 with the RNAi Pathway
The biogenesis ofmiRNAsand theirmechanisms of
post-transcriptional regulation have been reviewed
elsewhere [46–48]. In mammalian cells, miRNAs are
generated from multiple intron specific regions or can
be transcribed from their own promoters. Similar to
host mRNAs, miRNA biogenesis relies on specific
transcription factors. RNA polymerase II or RNA
polymerase III (for specific miRNAs such as the
human chromosome 19 miRNA clusters that are
interspersed in Alu-rich repeats [49]) generates large
primary miRNA transcripts called pri-miRNAs. These
molecules contain long stem–loop-like structures,
which are important components for eventual recog-
nition by miRNA regulatory proteins. Similar to host
mRNAs, miRNAs are also processed to be capped
and poly-adenylated. The miRNA nuclear micropro-
cessor complex proteins are responsible for the
alterations of pri-miRNA transcripts. Specifically,
Drosha, a member of the RNase III nuclease super
family, and DiGeorge syndrome critical region 8
(DGCR8), a dsRNA (double-stranded RNA) binding
1180 Review: MicroRNAs and HIV-1 Infectionprotein, are directly responsible for the nuclear
processing events. Drosha is the core protein that
mediates the initiation step by cleaving the pri-miRNA
transcript into pre-miRNA transcripts that are about
70 nt long. This cleavage results in a 3′-end dinucle-
otide overhang, which is an important recognition
signal for nuclear export by Exportin 5. Drosha's
endonuclease functionality requires continued inter-
actionwithDGCR8. In addition,DGCR8enhances the
protein stability of Drosha. A member of the karyo-
pherin family of nuclear export binding proteins,
Exportin 5, binds both the pre-miRNA and the active
GTPase RAN-GTP in the nucleus, and this hetero-
trimeric complex is exported into the cytoplasm
through the nuclear pore complex. Upon reaching
the cytoplasm, a complex containing Dicer, a second
RNase-III-like enzyme, cleaves the pre-miRNA in an
event that is facilitated through Dicer's recognition of
the hairpin-loop structure on the pre-miRNA, as well
as themultidomain human TAR-RNAelement binding
protein (TRBP), generating a duplex that is the
foundation of a functional miRNA but that requires
additional processing to become a biologically active
product.
Dicer plays an essential role in unwinding the
duplex of the two pre-miRNA strands. The thermo-
dynamic stability and base-pairing affinities between
the two strands are important factors in determining
the active miRNA that gets incorporated into the
RNA-induced silencing complex (RISC). The strand
of the duplex structure with the less stable base pair
at the 3′-end is usually considered the active miRNA
or the “guide” strand, while the other is called
miRNA* or “passenger” strand. Although both
strands can be functional, the role of the passenger
strand or the miRNA* (miRNA star partner) remains
to be fully elucidated. The active miRNA is then
recruited into the multi-protein RISC, where it binds
to the target mRNA to functionally regulate protein
expression. The RISC complex contains members of
the Argonaute (Ago) family of proteins as the catalytic
subunits (Ago1–Ago4), which have been shown to
have endonuclease activity. Among them, Ago2 plays
a fundamental role in the cleavage of the target
mRNAs, while TRBP, which can bind dsRNAs, plays
an important role by binding to and recruiting Dicer
and Ago2 to the RISC. When miRNAs bind to the
target mRNAwith perfect sequence complementarity,
the result is endonucleolytic cleavage of the mRNA.
However, imperfect complementarity results in rapid
polyadenylation of the target mRNA, leading to
repression of protein translation. Growing evidence
suggests thatmost endogenously expressedmiRNAs
interact with host mRNAs by imperfect complemen-
tarity and therefore may preferentially regulate protein
expression by translational repression.
Exceptions to the aforementioned canonical se-
quence of events are emerging. Dicer-independent
processing and expression of functional miRNAshave been noted [50,51]. For instance, the require-
ment of Drosha's processing of pri-miRNA into
pre-miRNA does not seem to be universal. Evidence
suggests that Drosha-independent, functional miR-
NAs do exist, the so-called “Mirtrons”. These are
genes that encode for miRNAs in their introns.
Post-splicing, the intron-derived miRNAs mimic the
structural features of pre-miRNAs; thus, they can be
exported to the cytoplasm and enter the miRNA-
processing pathway without Drosha-mediated cleav-
age [52–54]. Although the existence of a few tens of
mammalian Mirtrons has been characterized, further
research is needed to understand the biological
significance of these miRNA entities that are very
likely to grow in number and potential biological
relevance [55]. Finally, another non-canonical pro-
cessing pathway has shown the existence of splicin-
g-independent, Mirtron-like miRNAs called “Simtrons”
that do not seem to require most of the proteins in the
canonical miRNA pathway such as DGCR8, Exportin
5, Ago2 or Dicer, although they do require Drosha-
mediated cleavage for efficient functionality [56].
While the miRNA biogenesis and mechanisms of
regulation have been well studied, it is likely that our
knowledge on the proteins that participate and
regulate these pathways will continue to expand.
First discovered in plants and invertebrates and
eventually identified in mammalian cells as well,
miRNAs have been shown to play a crucial role in
the innate antiviral defense [57–59]. Thus, it is not
surprising to find evidence that multiple viruses have
developed mechanisms by which they can subvert
the cellular miRNA functionality, as a survival
strategy to evade RNAi-mediated antiviral re-
sponses [60–63]. A classic example of the crucial
importance played by cellular miRNAs during HIV-1
infection was demonstrated by Triboulet et al.; by
knocking down two important miRNA processing
proteins, Drosha and Dicer, they reported a significant
enhancement of viral replication in peripheral blood
mononuclear cells (PBMCs) from HIV-1-infected
patients and in latently infected cells [64]. In addition,
the same group has demonstrated that (i) HIV-1
mRNA binds to and co-localizes with proteins of the
RISC complex such as Ago2 and that (ii) several
proteins required for miRNA-mediated silencing (or
miRNA effectors) negatively regulate HIV-1 gene
expression by preventing viral mRNA association
with polysomes [65]. Interestingly, they also showed
that knockdown of some of these effectors led to virus
reactivation in PBMCs isolated from HIV-1-infected
patients undergoing suppressive cART. These stud-
ies underscore the importance of miRNAs in modu-
lating HIV-1 infection. Not surprisingly, HIV-1 seems
to have evolved several counteracting mechanisms
that promote its survival (Fig. 1).
Thus, the viral protein Tat has been shown to
physically interact with Dicer and to inhibit its activity.
















Fig. 1. Impact of HIV-1 on proteins involved in miRNA biogenesis pathway. Proteins in the RNAi machinery such as
Dicer and Drosha seem to play a role in controlling HIV-1 replication. Infection of HIV-1 has not been reported to
significantly alter the levels of nuclear microprocessor proteins DGCR8 and Drosha. Apart from regular translational
activities, post-nuclear export of HIV mRNAs, the HIV-1 TAR RNA element is also expressed. TAR binds to the
cytoplasmic RISC protein TRBP, which is essential for efficient cellular miRNA processing. Furthermore, upon
transcriptional up-regulation, the cytoplasmic protein Dicer processes TAR element for efficient functioning. HIV-1
transactivating protein Tat inhibits Dicer expression, although the mechanism is not well characterized. HIV-1 Vpr has
been shown to interact with the CRL4/DCAF4 E3 ubiquitin ligase complex, which results in poly-ubiquitination and
degradation by the proteasome.
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inhibited Dicer and had a “suppressor of RNA
silencing” (SRS) (or “RNA silencing suppressor”,
RSS) function [66]. Subsequently, they showed that
HIV-1 Tat–Dicer interaction was dependent on the
ability of Tat to bind host mRNAs and the helicase
domain of Dicer but independent of its transactiva-
tion domain [67]. In addition, other studies have
shown that the SRS/RSS function of Tat results in
altered miRNA expression profiles in T cell lines and
in primary PBMCs [68]. However, others have failed
to replicate these effects since it has also been
reported that Tat does not affect the global miRNA
expression profiles in human cell lines or PBMCs
and does not modify the expression of endogenous
or exogenous miRNAs [69,70] and that exposure of
human microglial cells to Tat does not directly affect
the protein levels of Drosha and Dicer [71].Besides Tat, the viral protein R (Vpr) has been
reported to also have SRS/RSS function by altering
expression of Dicer. Coley et al. showed that Vpr
(but not Tat, Nef or Env) is required to significantly
reduce Dicer levels upon HIV-1 infection of macro-
phages [72]. Very recently, it was reported that HIV-1
Vpr reduces Dicer expression by interacting with the
CRL4/DCAF1 ubiquitin ligase complex to target it for
proteasomal degradation, and this in turn results
in enhanced HIV-1 infectivity in macrophages [73].
Nonetheless, changes in miRNA expression profiles
upon HIV-1 infection in lymphocytes had been
shown to be independent of Vpr expression [68].
Discrepancies arising between some of the above-
reported studies might be related with differences in
the cell type being studied or in the expression levels
of the effector proteins in the RNAi machinery among
those cell types. For instance, Dicer expression is
1182 Review: MicroRNAs and HIV-1 Infectioninherently undetectable in primary monocytes (regu-
lated by endogenous miR-106a) and its expression is
significantly increased upon monocyte differentiation
into macrophages [72]. Greater consistency in the
strain of HIV-1 utilized for infection, the cell types
under study and infection and activation status of the
cells, needs to be achieved in order to better
understand the specific changes in the levels and
functionality of components of the RNAi machinery
upon HIV-1 infection. Finally, the impact of HIV-1 on
the nuclear proteins essential for successful expres-
sion of cellular miRNAs, such as Drosha and DGCR8,
is not well characterized. Dicer-independent process-
ing and expression of functional miRNAs have been
well noted [50,51], while very few miRNAs (such as
Mirtrons) have been shown to be functional without
the requirement of Drosha and DGCR8. Even though
Drosha and DGCR8 knockdown seems to enhance
HIV-1 infection, the role of these nuclear miRNA-
processing enzymes in HIV-1 infection is not
completely understood. It will be interesting to explore
if HIV-1 RNA or viral proteins such as Tat or Vpr can
bind to andmodulateDroshaandDGCR8expression.
Future experiments addressing these questions
would shed light on the importance of Drosha in
HIV-1 infection and would further enhance our current
understanding of the interaction of HIV-1 with the host
RNAimachinery. Overall, HIV-1-mediatedmodulation
of cellular miRNAs, although not directly essential for
basic replication stages, could play a role in patho-
genesis and disease progression.Does HIV-1 Express Functional Viral
miRNAs? The Controversy Ensues!
Members of several families of viruses encode viral
miRNAs or vmiRNAs. These vmiRNAs have crucial
roles in controlling viral replication, evasion of immune
responses and successful survival in the host [74,75].
The vmiRNAs have been better characterized in DNA
viruses including members of the Herpesviridae,
Polyomaviridae and Adenoviridae families [76–78].
On the other hand, encryption of miRNAs in their
genomes by RNA viruses remains controversial. RNA
viruses such as hepatitis C virus (HCV), yellow fever
virus and HIV-1 have been shown not to encode for
any functional miRNAs [79]. Various reasons have
been suggested to explain whyRNA virusesmight not
express miRNAs. The lack of nuclear localization by
most RNA viruses, since replication takes place in
the cytoplasm, prevents the interaction of the viral
RNA with the nuclear microprocessor proteins such
as Drosha and TRBP. However, RNA viruses that
replicate in the nucleus such as influenza virus still
do not seem to encode for a functional miRNA [80].
In addition, inclusion of a non-coding region for a
functional miRNA might result in degradation of the
entire viral RNA by traditional RISC-mediated mech-anisms. Therefore, it has been generally accepted
that RNA viruses do not encode vmiRNAs [81].
However, it was speculated that HIV-1might encode
for functional vmiRNAs because, as a retrovirus, the
viral RNA is reverse transcribed into a double-stranded
DNA form that is imported into the nucleus and
integrated in thehost genome.Therefore,HIV-1 should
have access to both the nuclear and cytoplasmic RNAi
machinery components, similar to host miRNAs. The
oncogenic retrovirus bovine leukemia virus encodes
an RNA pol III-transcribed miRNA cluster that is
functionally similar to the human miR-29 and contrib-
utes to development of B cell tumors [82]. Computa-
tional algorithms have predicted that HIV-1 can encode
five candidate pre-miRNAs [83]. In addition, the viral
protein Nef has been reported to encode a vmiRNA
(Nef-U3-miR-N367), which targets the Nef protein for
degradation and decreases viral replication through
various mechanisms [84,85]. Interestingly, synthetic
dsRNAs constructed with mutated Nef genes derived
from long-term non-progressors (LTNPs; HIV-1-
infected patients who are naïve to cART but do not
progress to AIDS [86]) seem to have a better ability to
target homologous sequences of mRNA than the
full-length, non-mutated Nef dsRNA, suggesting that
they could interfere with HIV-1 transcription and play a
role in the non-progression to AIDS of LTNPs [87].
However,whether thisNef-encoded vmiRNAcould be
responsible for, or at least contribute to, the reduced
disease severity in LTNPs needs to be experimentally
addressed. Also, if a Nef-encoded miRNA can inhibit
viral replication, it might play a crucial role in
establishment of HIV-1 latency.
Furthermore, Kaul et al. have discovered another
HIV-1-encoded pre-miRNA sequence in the 3′-end
of the viral genome, named hiv1-miR-H1, which has
been reported to (i) target selectively and specifically
the apoptosis antagonizing transcription factor that
plays an important role in controlling cellular apo-
ptosis; (ii) suppress important cellular proteins such
as c-myc, Par-4, Bcl-2 and the RISC protein Dicer;
and (iii) down-regulate the cellular miRNA miR-149
that can target the HIV-1 Vpr [88]. The authors
proposed that this HIV-1-encoded vmiRNA seems to
start an “epigenomic pathway” that leads mononu-
clear cells to initiate their apoptosis. In addition, while
precursor miRNA sequences in non-coding regions
of viral genomes seem usual, a unique recent
publication by Holland et al. reported that HIV-1
Env and Gag-Pol protein coding regions can encode
for several miRNA-like sequences [89]. Interestingly,
the Env coding region of five HIV-1 genomes (viral
strains of African origin) had near-perfect sequence
similarity to the human cellular miR-195. Moreover,
four other human miRNA-like sequences (similar to
the human miR-30d, miR-30e, miR-374a and
miR-424) were identified within the Env and Gag-Pol
coding regions of several HIV-1 strains, albeit with
lesser homology [89].
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RNA-15/16/195/424/497 family cluster that has been
previously confirmed to have potent roles in cell cycle
and apoptosis by regulating the expression of various
proteins such as WEE1, CDK6, cyclin D1, E2F3 and
Bcl-2 [90,91]. Interestingly, miR-195 is predicted to
potentially target the RISC protein TRBP, the dead-
enylase CCR4-NOT's complex protein CNOT6L and
the DNA helicase protein DDX3, as determined by
using the sequence-complementarity-based, miRNA
target prediction algorithmTargetscan† (Refs. [92–95];
personal observation). TRBP and CCR4-NOT play an
important role in miRNA-mediated gene silencing
pathway as previously noted. DDX3 has been shown
to have an essential role in HIV-1 replication for
efficient export of viral mRNAs [96]. Although the
existence of miR-195-like sequences in the viral
genome has been reported, it has not been exper-
imentally confirmed whether or not they are expressed
orwhether theyactually performanybiological function
in the context of HIV-1 infection. However, it is
important to highlight that, if this vmiRNAcould function
similarly to the host miR-195, it might have potent roles
in regulating the above indicated proteins and modu-
lating the cell cycle status of infected cells.
HIV-1 encodes a transactivation RNA (TAR)
element that contains the binding region for the
viral protein Tat. In infected cells, the TAR element in
nascent viral RNAs recruits Tat, which mediates
transactivation of the viral promoter by recruiting the
cyclin-dependent kinase CDK9 (a component of
P-TEFb) and Cyclin T1 [97]. In addition, the TAR
element has a structure similar to endogenous Dicer
substrates with an imperfect 50-nt stem–loop region
[98] and was computationally predicted to be one of
the five regions in the HIV-1 genome that could
interact with Dicer [83]. The HIV-1 TAR element's
interaction with TRBP, a TAR-RNA binding protein
(TRBP) and the humanhomologue of theDrosophila's
Loquacious protein, is important since TRBP binds to
Dicer for optimal incorporation of mature miRNAs into
RISC [99,100]. Interestingly, Klase et al. reported that
HIV-1 TAR element is processed by Dicer and results
in the formation of a virally encoded miRNA that
participates in chromatin remodeling of the viral LTR
[101], and they suggest that Dicer may be essential
for successful HIV-1 infection since its levels are
sub-optimal in monocytic cells, which are relatively
resistant to productive HIV infection. The functional
relevance of this interaction is supported by the fact
that, when siRNA was used to knockdown TRBP in
susceptible cells, HIV-1 replication and virus produc-
tion were inhibited [102], and it has later been shown
that TRBP promotes HIV-1 replication by down-reg-
ulating the dsRNA-dependent antiviral protein kinase
PKR [103]. In addition, it has been reported that the
TAR element goes through specific asymmetrical
processing by Dicer and produces two strands of
the TAR-miRNA, namely TAR-miR-5p and 3p, withmiR-TAR-3p having been described to have greater
silencing capacity [104,105]. Therefore, the TAR-
miRNA would be an additional vmiRNA that might
have important functions inHIV-1 replication, although
the exact molecular mechanisms of this vmiRNA are
not completely understood.
Finally, two recent studies provide further insight into
this field. Schopman et al. have used the extremely
sensitive SOLiD™ 3Plus System to analyze viral RNA
accumulation in infected T lymphocytes and reported
the detection of numerous sncRNAs derived from the
HIV-1 genome, which could correspond to both viral
miRNAs and siRNAs with potentially functional rele-
vance for viral production [106]. The other study by
Althaus et al. used a novel, sequence-targeted
enrichment strategy to capture, clone and sequence
HIV-1-derived sncRNAs from HIV-1-infected primary
CD4+ T lymphocytes and macrophages, and it
reported the finding of several hundred sncRNAs
ranging in length between 16 and 89 nt [107].
However, their potential relevance is unknown.
Despite the evidence noted above, controversy
over whether or not HIV-1 truly encodes functional
vmiRNAs persists since (i) there is a lack of
authoritative experimental demonstrations on the
functional relevance of the vmiRNAs reported above
and (ii) other evidence suggesting that HIV-1 does not
encode for any functional miRNA has been reported.
Contrary to the results presented above, Lin et al.
showed that neither HIV-1 nor another member of the
retroviral family, human T cell leukemia virus type 1,
expresses any virally encoded siRNA-like or miRNAs
in persistently infected T cells [69]. Of note, this report
also dismissed the expression of HIV-1 TAR-miRNA
in these infected cells. However, Harwig et al. have
used the very sensitive SOLiD™ ultra-deep sequenc-
ing technology and confirmed the expression of a
TAR-specific miRNA in HIV-1-infected cells [108].
Very recently, Whisnant et al. used deep sequencing
in two infected cell lines and in primary PBMCs and
macrophages and concluded that HIV-1 does not
encode for any vmiRNAs in infected cells [109]. Even
though they did detect that the HIV-1 genome
contains binding sites for cellular miRNAs using
photoactivatable, ribonucleoside-induced cross-link-
ing and immunoprecipitation technology, they dem-
onstrated that viral transcripts remained largely
refractory to miRNA binding, probably due to their
extensive secondary structure. There is therefore an
urgent need in the field to standardize analyses and
perhaps sharing of biological samples and expertise
to try to clarify the discrepancies related to HIV-1-en-
coded vmiRNAs and their potentially functional
relevance.
Meanwhile, Narayanan et al. very recently report-
ed that the TAR-miRNA gets packaged in exosomes
released from HIV-1-infected cells [110]. Exosomes
are small, cell-derived vesicles that are produced
as a natural mode of intercellular communication
Fig. 2. Cellular miRNAs may modulate HIV-1 infectivity and replication. HIV-1 infection can be directly affected by
cellular miRNAs that can target HIV-1 viral RNA through base pair complementarity (indicated in green). In addition, other
miRNAs can inhibit host proteins that play an active role during productive HIV-1 infection and thereby indirectly inhibit
HIV-1 replication (indicated in red). More recently, few miRNAs that can enhance HIV-1 infection have also been identified
(indicated in blue). The mechanisms underlying these pro-HIV-1-miRNAs have not been well defined, but it is possible that
these miRNAs can bind to and suppress negative regulators of HIV-1 infection. Finally, HIV-1-encoded vmiRNAs such as
HIV1-miR-H1 and TAR-miRNA might also modulate viral infectivity. Further research is needed to elucidate the specific
mechanisms by which these vmiRNAs and many cellular miRNAs might affect HIV-1 infectivity and replication.
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contain proteins and nucleic acids, including miRNAs,
which can be taken up by other cells and result in a
modulation of their functionality [113,114]. Therefore,
TAR-miRNA-containing exosomes released from
HIV-1-infected cells might be modulating uninfected
cells, perhaps to increase their susceptibility to
infection. Further research needs to be performed to
confirm these findings and to clarify the potential
biological significanceof theseTAR-miRNA-containing
exosomes in HIV-1 infection and pathogenesis.Impact of Cellular miRNAs on HIV-1
Infection
Cellular RNAi machinery such as miRNA plays
crucial roles in controlling viral infection in general,
and HIV-1 may be no exception. The interactions
between HIV-1 and the host cellular miRNAs have
been studied, if not extensively, at least in some
detail. However, it still remains a quite complex issueand it is likely that we may actually have only been
scratching the surface of their relationship. A number
of cellular miRNAs have been shown to play a role
in modulating HIV-1 infection, either directly or
indirectly. In this section, we review the reported
impact of miRNAs on HIV-1 (Fig. 2) and discuss
potential experimental avenues for future research.
miRNAs that directly target HIV-1
Cellular permissiveness to HIV-1 infection mainly
depends on the expression of adequate levels of
the primary receptor CD4 and one of the main
co-receptors, the chemokine receptor CCR5 or
CXCR4. However, the activation and differentiation
status of the cells are known to influence their
permissiveness to HIV-1 infection. For instance,
monocytes are quiescent cells and do not generally
support productive HIV-1 infection; however, they
become highly susceptible upon differentiation into
macrophages [115–118]. Similarly, resting CD4+ T
cells do not support productive HIV-1 replication
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activated CD4+ T cells [119,120]. Although in-
creases in cell surface expression of receptors
CD4, CCR5 and/or CXCR4 have been implicated
in enhanced susceptibility to infection, more intrinsic
factors have also been reported to play a significant
role in determining cell-type-specific HIV-1 restric-
tion [121–125]. In this sense, in a ground-breaking
study by Huang et al., a selected group of miRNAs
were shown to play an active role in modulating
HIV-1 infectivity of resting CD4+ T lymphocytes
[126]. They reported that a group of cellular miRNAs,
including miR-28, miR-125b, miR-150, miR-223
and miR-382, had the ability to bind to the 3′ UTR
of viral mRNAs through sequence complementarity
and showed that activation of resting CD4+ T cells
resulted in down-regulation of these miRNAs, which
correlated with enhanced HIV-1 susceptibility. Fur-
thermore, this translational repression mediated by
“anti-HIV-1 miRNAs” was proposed to be largely
responsible for HIV-1 latency in resting CD4+ T cells,
since experiments in which all five of these miRNAs
were inhibited in resting CD4+ T cells from cART-
treated individuals (with undetectable viremia) dis-
played enhanced HIV-1 production. The authors
thus suggested that these novel anti-HIV-1 miRNAs
could play a role in controlling HIV-1 latency, at
least in these cells, and that their manipulation could
potentially contribute to the purging of viral reservoirs
[126]. In a similar study, Wang et al. showed that
this group of anti-HIV-1 miRNAs were enriched in
monocytes as compared to monocyte-derived mac-
rophages [127] (macrophages differentiated from
blood-derived monocytes in the presence of macro-
phage colony-stimulating factor in the cell culture
medium). The authors reported that macrophages
down-regulated these miRNAs upon differentiation
and that this down-regulation was related with their
ability to support productive HIV-1 infection. By
combinatorial inhibition of these miRNAs, they also
showed that monocytes had a limited increase in their
susceptibility to HIV-1 infection [127]. However, it
should be pointed out that a direct response to the
original publication questioned that the magnitude of
the changes observed in miRNA over-expression or
inhibition experiments does not support the conclu-
sions and that the authors did not consider the
contribution of themodulation of the levels of receptors
to the observed effects [128]. More recently, Sisk et al.
published new experimental data and the results of a
re-analysis of publicly available datasets suggesting a
more complex scenario than that presented above
with a uniform down-regulation of anti-HIV-1 miRNAs
during the differentiation from monocytes to macro-
phages [129]. This study could only confirm that
miR-223 is down-regulated in macrophages, while
the rest of the miRNAs in question were either more
abundant or unchanged in macrophages than in
monocytes [129]. These discrepancies point again tothe need for more standardized future studies that
should ideally take into consideration the potential
differences that may stem from the various available
platforms for studying miRNAs, diverse experimental
details in the monocyte isolation and/or in the
monocyte-to-macrophage differentiation protocols,
possible alterations in abundance of macrophage
subpopulations and so on.
Modulation of these anti-HIV-1 miRNAs in re-
sponse to various stimuli has also been reported to
alter HIV-1 infectivity. Since drugs of abuse are
intimately linked to the HIV-1 epidemic and are
known to affect multiple aspects related to disease
progression such as adherence to therapy, cogni-
tion, risk behaviors and so on, some studies have
investigated the potential effects of drugs of abuse
on expression of miRNAs that may be important for
HIV-1 infection and replication. For instance, treat-
ment of monocytes with morphine has been shown
to lead to a reduction in expression of miR-28,
miR-125b, miR-150 and miR-382, a subset of the
anti-HIV-1 miRNAs reported in monocytes by the
same group, and to enhance the susceptibility to
infection of monocytes [130]. Furthermore, they also
observed that PBMCs from uninfected, heroin-
abusing individuals have lower levels of these
miRNAs than those of healthy, non-abusing individ-
uals, supporting their in vitro findings. Another com-
monly abused drug, cocaine, was also shown to inhibit
one such anti-HIV-1 miRNA, miR-125b, in CD4+ T
cells, and subsequent experiments with a T cell line
showed that miR-125b knockdown enhances HIV-1
replication, whereas its over-expression decreases
HIV-1 replication [131]. Therefore, the authors sug-
gested that miR-125b could be a key player for the
cocaine-induced enhancement of HIV-1 replication in
CD4+ T cells. Other modulators of anti-HIV-1 miRNAs
include cytokines and Toll-like receptor (TLR) ligands.
For example, stimulation of TLR3was shown to induce
an anti-HIV-1 effect in primary macrophages, partially
through up-regulation of the set of anti-HIV-1 miRNAs
mentioned above [132]. Interestingly, up-regulation of
these four anti-HIV-1 miRNAs was also reported in
macrophages treated with type I interferons (IFN),
IFN-α and IFN-β, and was shown to partially contribute
to inhibition of HIV-1 infection in primary macrophages
[133].
Another cellular miRNA that can directly target the
3′ UTR of viral mRNAs is miR-29. Binding of miR-29
to the HIV-1 mRNA has been shown to increase its
association with proteins in the RISC complex and to
augment its incorporation into processing bodies
(or P bodies, cytoplasmic domains that contain
proteins involved in post-transcriptional processes
such as mRNA degradation, translational repression
or RNA-mediated gene silencing), thereby inhibiting
translation of viral proteins and viral replication [134].
Also, an independent study had shown that inhibition
of miR-29a significantly enhanced HIV-1 infection,
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regulates the expression of Nef protein [135].
miRNAs that affect HIV-1 infection by modulating
the expression of HDFs
By utilizing genome-wide RNAi screens, various
groups have identified many host factors that seem
to be required for, or at least to participate to a
certain extent in, one or more steps of the viral life
cycle [22–30]. Although there was a limited overlap in
the factors identified in the various screens, these and
subsequent studies have certainly determined the
role of some critical cellular factors and pathways
during the HIV-1 life cycle, opening the door to new
opportunities to curb productive HIV-1 infection
through the targeting of the interactions of HIV-1 with
these crucial HDFs [136]. Since miRNAs play such an
important role in modulating cellular protein expres-
sion, it is not surprising that, during the last few years,
several cellular miRNAs have been reported to
regulate HIV-1 infection, indirectly, through the mod-
ulation of the levels of HDFs.
Cyclin T1 is an important component of the
eukaryotic RNA polymerase II elongation complex
through its association with CDK9. This heterodimer
forms the positive transcription elongation factor B or
p-TEFb [137,138]. The role of the p-TEFb complex in
interacting with the HIV-1 TAR element and the viral
protein Tat to facilitate viral transcription has been
extensively characterized [139–141]. RNAi-mediated
inhibition of this complex has been reported to inhibit
HIV-1 replication [142], and relatively higher expres-
sion of Cyclin T1 in HIV-1 susceptible cells such as
macrophages, as compared to monocytes, has also
been reported [143]. Sung et al. identified a novel
anti-HIV-1 role for miR-198 through down-regulation
of Cyclin T1; they first observed an inverse correlation
between the levels of Cyclin T1 and miR-198 in
monocytes and macrophages, and subsequently, it
was shown that miR-198 binds to the 3′UTR of Cyclin
T1 mRNA and reduces its protein levels [144]. In
addition, the authors provided evidence that miR-198
over-expression inhibited HIV-1 replication in macro-
phages, supporting the concept that miRNAs exert
cell-type-specific effects [144]. Chiang et al. have also
reported that miR-198 is expressed at very low levels
in resting CD4+ T cells and is not modulated upon
activation [145]. However, they identified another
miRNA, miR-27b, which, in addition to other previ-
ously reported anti-HIV-1 miRNAs such as miR-29b,
miR-150 and miR-223, inhibited the expression of
Cyclin T1 in resting CD4+ T cells. They reported that
activation of CD4+ T cells resulted in down-regulation
of these miRNAs and a subsequent up-regulation of
Cyclin T1, which correlated with enhanced HIV-1
susceptibility [145].
Interactions of the HIV-1 protein Tat with transcrip-
tional co-activators such as cellular CREB bindingprotein p300 and p300-CREB binding protein asso-
ciated factor (PCAF) have been shown to be
important for Tat acetylation and eventual HIV-1
LTR-driven transcriptional up-regulation [146,147].
Interestingly, the cellular miRNA cluster miR-17/92
has been reported to target PCAF and to inhibit
HIV-1 infection [64]. Specifically, miR-17-5p and
miR-20a over-expression resulted in reduced mRNA
levels and protein output of PCAF. Of note, HIV-1
infection actively suppressed these miRNAs to
enhance its infectivity by usurping the p300/PCAF
complex for efficient viral translation [64].
Another well-characterized HDF is the purine-rich
element binding protein α (Pur-α), a sequence-spe-
cific DNA and RNA binding protein. It has been
previously noted to bind to the HIV-1 TAR element
and the viral Tat protein in the nucleus of infected
cells to facilitate viral transcriptional up-regulation
[148,149]. Recently, it was reported that expression
of Pur-α was significantly lower in monocytes than in
monocyte-derived DCs and that this difference
contributed to the lower susceptibility to HIV-1
infection in monocytes, with the mechanism being
attributed to higher expression levels of several
cellular miRNAs (miR-15a, miR-15b, miR-16,
miR-20a, miR-93 and miR-106b) that target Pur-α
mRNA [150]. Accordingly, inhibition of these miRNAs
in monocytes enhanced expression levels of Pur-α
and also led to increased HIV-1 infection.
Unlike all the miRNAs reported above that target
transcription, recent studies from our laboratory have
resulted in the identification of a novel anti-HIV-1 role
for the cellular miRNA miR-155, which seems to
inhibit HIV-1 at a step prior to the integration of the
viral cDNA into the host genome. miR-155 is also
known as an onco-mir since it has been found
altered in many cancers but is also crucial to
establish appropriate immune responses (reviewed
by O'Connell et al. [40]). For instance, miR-155
levels increase in the human monocytic cell line
THP1 and in murine bone-marrow-derived macro-
phages in response to stimulation with LPS and
poly(I:C), TLR4 and TLR3 ligands, respectively, and
it seems to play a fundamental role in the macro-
phage inflammatory profile [151,152]. In addition, in
DCs, miR-155 targets the transcription factor PU.1
and subsequently down-regulates the expression of
DC-specific intercellular adhesion molecule-3 grab-
bing non-integrin (or DC-SIGN) [153], which binds to
the HIV-1 envelope glycoprotein gp120 and is
important in the process of trans-infection [154].
We identified that activation of TLR3 in primary
human macrophages resulted in significant en-
hancement of miR-155 expression levels, which
correlated with decreased HIV-1 infectivity [155].
Through over-expression studies, as well as inhibi-
tion of miR-155 in the context of TLR3 stimulation,
we demonstrated that miR-155 inhibits HIV-1 at a
post-entry, pre-integration step. Further analysis
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mRNAs of at least three known HDFs, the cellular
transcriptional co-activator lens epithelium-derived
growth factor (LEDGF)/p75, ADAM10 (a member of
a disintegrin and metalloprotease family of proteins)
and the nucleoporin NUP153, and reduced the
levels of protein expression of all three HDFs in
primary macrophages [155]. Combinatorial inhibition
of these three HDFs by miR-155 or by siRNA
resulted in accumulation of late reverse transcripts
and significantly decreased viral integration, in agree-
ment with the roles of these HDFs in trafficking and/or
nuclear import of HIV-1 PIC [155].
Finally, an attractive target among all known HDFs
is the chemokine receptor CCR5 that serves as the
major co-receptor for HIV-1 infection since it is known
that individuals homozygous for a 32-base-pair
deletion in CCR5 are resistant to infection by
CCR5-using HIV-1 strains. In fact, treatment of
CD4+ T cells with zinc-finger protein nucleases
specifically disrupting the CCR5 coding sequence
induces resistance to CCR5-using HIV-1 infection
in vitro and in vivo [156–158]. As an alternative to this
genetic modification, cellular miRNAs that target
CCR5 mRNA could potentially be used to reduce
CCR5 levels and test experimentally whether it might
have an impact on reducing HIV-1 entry and infection.
miRNAs that enhance HIV-1 infection
Very few studies have reported miRNA-mediated
enhancement of HIV-1 infection. Recently, miR-132
was shown to enhanceHIV-1 infection [159]. miR-132
expression was reported to be significantly higher in
activatedCD4+ T cells than in resting cells. In addition,
ectopic expression of miR-132 in Jurkat T cells was
also shown to increase HIV-1 infection [159]. Howev-
er, the mechanisms underlying this effect have not
been uncovered. It would be interesting to determine
the specific step on the viral life cycle that seems to be
potentiated by miR-132. To this end, the authors
showed preliminary data wherein miR-132 over-
expression decreased the expression of a cellular
protein MeCP2. MeCP2 is a methyl CpG binding
cellular protein. The role ofMeCP2 in regulating HIV-1
replication was shown by experiments in which
siRNA-mediated inhibition of MeCP2 enhanced
HIV-1 replication [160]; however, the specific role of
miR-132 andMeCP2 inHIV-1 replication has not been
identified. Recent evidence suggests that MeCP2
directly binds to LEDGF/p75 (a previously character-
ized HDF that interacts with the HIV-1 protein
integrase and promotes viral nuclear import and
integration) and significantly enhances MeCP2's
transcriptional activity [160]. MeCP2 binds to LEDGF
in its N-terminal region, whereas the integrase binding
domain in LEDGF is located in the C-terminus [161].
Therefore, it is not likely that MeCP2 might be
competitively binding to LEDGF in place of HIV-1integrase. However, the N-terminus of LEDGF also
contains the nuclear localization sequence, making it
possible that the binding of MeCP2 might alter other
functions of the protein that would indirectly affect the
role of LEDGF in the HIV-1 life cycle. In addition, it
would be interesting to determine if LEDGF is involved
in the augmented HIV-1 replication observed in
MeCP2-silenced cells.
The only other example in the literature relates to
the sirtuin 1 (SIRT1)-mediated regulation of HIV-1
Tat transactivation. The viral protein Tat is active in
its acetylated form (regulated by p300/PCAF com-
plex), and SIRT1 is a class III deacetylase depen-
dent on nicotinamide adenine dinucleotide that has
been characterized to regulate HIV-1 transcription
by deacetylating Tat [162]. Interestingly, miR-217
and miR-34a were recently shown to be significantly
up-regulated upon Tat exposure and to have the
ability to bind the 3′ UTR region of SIRT1 mRNA and
inhibit its expression, thereby enhancing HIV-1
Tat-mediated transactivation [163,164]. The func-
tional relevance of cellular miRNAs that target SIRT1
was shown by a recent report characterizing simian
immunodeficiency virus (SIV) encephalitis. In this
study, the authors demonstrated a significant up-
regulation of miR-142 post-SIV infection that leads to
down-regulation of SIRT1, which could potentially
contribute to SIV replication and SIV-induced en-
cephalitis [165]. In addition, SIRT1 is regulated by
another cellular protein, nicotinamide phosphoribo-
syltransferase (NAMPT), which plays a role in
maintaining the cellular levels of nicotinamide
adenine dinucleotide. A recent study showed that
miR-182 targets the 3′ UTR region of NAMPT mRNA
and inhibits its expression [166]. Interestingly, Tat
significantly up-regulated the levels of miR-182
expression, and down-regulation of NAMPT by
miR-182 led to decreased expression of SIRT1
levels, which in turn enhanced HIV-1 Tat transacti-
vation [166].
Overall, there are cellular miRNAs that have been
reported to modulate HIV-1 infection, but this field
promises to rapidly expand in the near future. As
evidenced in this section, cell-type-specific expres-
sion of miRNAs and HDFs seems to contribute in
determining HIV-1 susceptibility. It is also important
to consider the activation and differentiation status of
the cell when studying miRNA-mediated restriction
or enhancement of HIV-1 infection. Furthermore,
attention to the role of cellular restriction factors has
grown exponentially in the recent past since they limit
HIV-1 infection by multiple mechanisms and their
expression may vary between different cell types,
likely contributing to determine the cellular suscepti-
bility to productiveHIV-1 infection. As expected, HIV-1
seems to have evolved many specific mechanisms of
evasion from restriction factor-mediated inhibition
[167,168]. An interesting avenue for future research
that has not yet been explored is to investigate if HIV-1
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alter the expression of restriction factors. Character-
izing the potential for HIV-1-mediated enhancement of
these miRNAs might help uncover important roles in
enhanced viral replication, pathogenesis and survival
of the virus.miRNA Profiles in HIV-1-Infected Patient
Cohorts: Potential Biomarkers?
In spite of the experimental evidence characteriz-
ing the importance of cellular miRNAs on HIV-1
infection in in vitro and ex vivo studies, only a limited
number of reports have attempted to explore global
miRNA profiles in HIV-1-infected patients. Houzet et
al. published one of the first reports profiling miRNA
expression in HIV-1 seropositive individuals [169].
By grouping patients into four categories based on
differential CD4+ T cell counts and viral load, the
authors compared miRNA expression profiles in
PBMCs and found that, of the 63 miRNAs that were
commonly altered, 59 miRNAs were down-regulated
and the rest were up-regulated in seropositive
individuals when compared to uninfected, healthy
controls [169]. Furthermore, they explored miRNA
changes in specific subsets of HIV-1 susceptible
cells and concluded that several T-cell-specific
miRNAs were down-regulated in all seropositive
individuals; these miRNAs included miR-150,
miR-191, miR-223, miR-16 and miR-146b [169]. Of
note, miR-150 and miR-223 are signature anti-HIV-1
miRNAs that have been reported to directly inhibit
HIV-1 transcription [126]. In addition, the authors
noted that the vast down-regulation of several
cellular miRNAs might be due to the down-regulation
of essential proteins in the miRNA machinery such
as Dicer and Drosha. As mentioned earlier, Triboulet
et al. showed that knockdown of Dicer and Drosha
enhancedHIV-1 infection of T cell lines [64]. Therefore,
it is possible that reduced levels of Dicer andDrosha in
PBMCs of HIV-1 seropositive individuals may lead to
reduced global miRNA levels, even though the study
by Houzet et al. was limited due to the small number of
patients included [169].
Elite suppressors (ES; also known as elite control-
lers) are agroupofHIV-1-infected patients that are able
to maintain extremely low to undetectable viral loads in
blood (b50 copies/ml, below the limit of detection of
commercial assays) for many years without cART and
generally do not show any clinical signs of disease
progression. Various innate and adaptive immune
factors inEShave been previously reported [170–172].
Therefore, it is important to understand the specific
mechanisms behind the differential evolution of HIV-1
infection in ES versus the rest of HIV-1-infected
individuals and potentially to exploit thesemechanisms
in the field of HIV-1 vaccine development. In this
regard, Witwer et al. have characterized global miRNAexpression profiles in PBMCs from HIV-1-infected
viremic patients and ES [173], to determine if
differential miRNA expression profiles in ES might
shed light on their resistance to virus-induced disease
progression. To increase reliability, the authors
employed three different miRNA amplification plat-
forms and were able to identify specific miRNAs that
were uniquely expressed in PBMCs from ES when
compared to viremic patients and uninfected controls.
Remarkably, signature anti-HIV-1 miRNAs miR-125b,
miR-150 and miR-29 were down-regulated in both ES
and viremic patients. Another important miRNA that
has been reported by our group to inhibit HIV-1
infection in macrophages, miR-155 [155], was signif-
icantly higher only in viremic patients as compared to
ES or healthy controls. Other miRNAs that were only
up-regulated in viremic patients include miR-9,
miR-34a and miR-181. Interestingly, miR-181
(miR-181abc and miR-181d) has been predicted to
bind to and potentially inhibit theHIV-1 restriction factor
SAMHD1 (personal observation). Increase in miR-34a
could possibly be explained by the recent evidence
suggesting that miR-34a is up-regulated by the viral
protein Tat, leading to down-regulation of SIRT1 and to
enhanced viral translation [163]. However, miR-31 and
miR-31*,which to date havenot been reported to play a
role in HIV-1 replication, were found to be significantly
reduced only in viremic patients, with respect to ESand
uninfected controls, perhaps suggesting a potential
functional relevance. In addition, the authors found
correlations betweenmiRNAchangesandplasmaviral
load and CD4+ T cell counts in these patients. Overall,
this study brought in the concept of using differentially
expressed miRNAs as biomarkers to predict the risk of
disease progression [173], although further studies are
needed to achieve this goal.
Similar to, but different from ES, LTNP are HIV-1
seropositive individuals that naturally control vire-
mia, but to detectable although low levels (10,000
copies of RNA/ml of blood) without cART, have
normal CD4+ T cell counts and do not experience
the typical disease progression of HIV-1-infected
individuals [86,174]. Additionally, multiply exposed
uninfected individuals (MEU) are those rare individ-
uals who have been potentially exposed to HIV-1 in
multiple occasions but remain HIV-1 seronegative.
Mechanisms underlying resistance to or efficient
control of HIV-1 infection in these patient cohorts
have not been well characterized. To this end,
Bignami et al. evaluated miRNA expression profiles
in CD4+ T cells from LTNP, naïve healthy individuals
and MEU individuals [175]. The authors found that
23 miRNAs were differentially expressed between
MEU and naïve healthy individuals. For example,
resting CD4+ T cells from MEU individuals had
significantly lower levels of miR-28-5p, miR-125b
and miR-223. Interestingly, only one miRNA,
miR-155, had significantly higher levels in LTNP
than in MEU. However, a response to this publication
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levels might be largely contributed to by effector/
memory regulatory T cell subsets (Tregs) [176] and
suggested that the changes in the prevalence of
CD4+ T cell subsets in response to HIV-1 infection
might be the major factor responsible for differential
miRNA expression profiles in these patient cohorts.
Furthermore, Bignami et al. showed that the miRNA
biogenesis proteins such as Dicer and Drosha are
significantly down-regulated in CD4+ T cells derived
from MEU individuals [175], although the mecha-
nisms are not well understood. Finally, in another
response to this study, Witwer et al. re-analyzed the
miRNA expression profiles and raised questions
regarding the validity of the conclusions since their
new analysis revealed that several previously
characterized miRNAs in HIV-1-infected individuals
such as miR-125b, miR-31, miR-146b and miR-29a
are actually lower in HIV-1-infected, cART naïve
patients [177].
Previous reports have demonstrated that an
increase in the levels of the cytokine IL-10 post-
HIV-1 infection plays a detrimental role by inhibiting
HIV-1-specific T cell responses [178]. A recent study
reported that IL-10 mRNA is directly targeted by the
Let-7 family of miRNAs and showed that enhance-
ment of IL-10 levels after in vitro infection with HIV-1
correlated with a decrease in Let-7 miRNA levels
[179]. In addition, it was shown that levels of Let-7
miRNAs were significantly lower in CD4+ T cells
from chronically HIV-1-infected patients as com-
pared to uninfected individuals and LTNP. There-
fore, they proposed that the decrease in Let-7
miRNAs might be directly responsible for enhanced
IL-10 production in HIV-1-infected cells [179].
Similarly, Seddiki et al. have reported that the
expression of B lymphocyte-induced maturation
protein-1 (BLIMP-1) is significantly increased, while
levels of miR-9 expression are significantly reduced,
in CD4+ T cells from chronically infected HIV-1
patients as compared to uninfected healthy individ-
uals or LTNP [180]. They showed that BLIMP-1
suppresses IL-2 (an important cytokine required for T
cell growth and survival) and implied that increased
BLIMP-1 expression in HIV-1-infected individuals
might contribute to virus-induced T cell dysregulation
through alterations in IL-2 levels. Also, the authors
demonstrated that cellular miR-9 directly binds to and
inhibits BLIMP-1, thereby uncovering a potential role
for miR-9 in HIV-1-infected patients [180].
Very recently, Duskova et al. have published a
global miRNA-mRNA expression profile study, com-
paringPBMCs fromchronicallyHIV-1-infectedpatients
and uninfected healthy controls. They demonstrated
that several miRNAs including miR-19b, miR-146a,
miR-615-3p, miR-382, miR-34a, miR-144 and
miR-155 were significantly increased in infected
patients as compared to healthy controls [181] and
also showed alterations in the levels of pro-inflamma-tory cytokines and chemokines, although the signifi-
cance of such findings is yet unclear.
Finally, a word of caution: the majority of the
studies mentioned above have characterized the
miRNA expression profiles in various groups of
patients and controls using PBMCs or purified CD4+
T cells, but only few miRNAs seem to be consistently
modulated. It needs to be considered that the cellular
isolation procedures might affect the outcome of
these analyses because miRNAs are tightly modu-
lated in specific cell types based on activation
stimuli, differentiation states or other changes in
the cellular environment. Thus, profiling miRNAs in
undefined, mixed cell populations such as PBMCs
(that may contain quite different frequencies of
specific cell types) will reduce the likelihood of
identifying potentially biologically significant chang-
es that may occur in individual cell types. This is in
agreement with a recent report that profiled miRNAs
and mRNAs in nine human immune cell subsets
derived from healthy donors and found that cellular
miRNA and mRNA expression patterns can be
highly specific to each of the cell subsets investigat-
ed [182]. In addition to considering the potential
variability between cell types, miRNA expression
analyses in patient cohorts should utilize stringent
criteria for data analyses and reliable expression
profiling techniques to ensure consistency between
multiple studies and patient cohorts. Lastly, it might
be beneficial if a consortium of basic investigators
and clinicians interested in profiling miRNA expres-
sion in HIV-1-infected patients could be established
in the future, to facilitate open discussion and
sharing of analysis tools, patient samples and gene
expression profiling information.miRNAs: Potential Therapeutic
Applications
HIV-1 infection of activated CD4+ T cells results in
rapid apoptotic death of infected cells and uninfected
bystander cells [183,184]. On the other hand,
HIV-1-infected macrophages, as innate immune
cells, are relatively resistant to cytopathic effects
induced by the virus. As resident innate immune
sentinels, macrophages are located in various
tissues including the brain and serve as HIV-1
reservoirs [185,186]. In addition, HIV-1 infection of
macrophages provides a niche for the virus to
undergo ample virus replication masking host
antiviral responses and anti-retroviral drugs
[115,187–190]. While infected macrophages and
DCs support active replication and play a role as a
reservoir throughout the body, the major latent
reservoir in infected patients is likely the resting
CD4+ T cells [11,14,116,191–195]. Latent reservoirs
of HIV-1 can be defined as cells that contain
successfully integrated HIV-1 genomes yet do not
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progeny virions. The lack of active viral replication in
an infected patient might be due to multitude of
reasons including cART, host restriction factors, host
antiviral immune responses and so on. Although an
infected patient on cART might have remarkably low
or even undetectable levels of virus in blood, the
presence of latent reservoirs enables the virus to be
“reactivated” upon certain conditions such as treat-
ment interruption or lack of adherence to the
prescribed cART and changes in cellular activation
states. While anti-retroviral drugs inhibit active viral
replication, they do not affect the integrated pro-
viruses, which have the potential to be reactivated to
produce newly infectious viruses when a more
favorable cellular environment arises [11,192,193];
therefore, there is a need to develop new strategies
that purge latent reservoirs and will bring us one step
closer to the real goal: a cure for HIV-1 infection
[2,196–198].
In addition, through the use of specific miRNA
mimics and inhibitors [199–204], the modulation of
miRNAs that regulate expression of HDFs could be
an attractive avenue for future research. If the HDFs
targeted by particular miRNAs are involved in the
pre-integration stages of the viral life cycle, they
would also have the advantage of resulting in
inhibition or reduction of integration, which would
suppress, or at least reduce, the pool of cells with
integrated pro-viruses that increase the size of the
viral reservoir and potentially the number of latently
infected cells that resist elimination during cART.
Furthermore, a single miRNA may be able to target
more than one HDF or several miRNAs with different
targets may be combined so that various proteins
involved in different steps of the viral life cycle can be
regulated, enabling a combinatorial, multi-target
approach that could complement current cART for
the inhibition of HIV-1 infection. One such example is
cellular miR-155, which binds to three HDFs, namely,
LEDGF, ADAM10 and NUP153, resulting in either
inhibition or large reduction in HIV-1 integration in
primary macrophages [155]. Up-regulating the ex-
pression of some miRNAs such as miR-155 could
also provide an additional benefit since it has been
well characterized that it inhibits the cellular protein
suppressor of cytokine signaling-1 (SOCS-1), a
negative regulator of the activity of type I IFNs.
Therefore, inhibiting this negative regulator of antiviral
cytokines would likely result in an augmented antiviral
state that could make the cells more refractory to
infection [205–207]. Furthermore, inhibition of select-
ed miRNAs can also be used to our advantage. For
instance, inhibition of miRNAs that target common
cellular antiviral proteins or pathways might enhance
the antiviral responses triggered by HIV-1 entry or
infection, which could result in an increased resis-
tance to productive infection. Finally, miRNAs that
may modulate the levels of known restriction factors,such as APOBEC3G, TRIM5α or SAMHD1, could be
of interest as well. It is plausible that HIV-1-infected
cellsmight secrete soluble factors such as type I IFNs,
which might down-regulate miRNAs that target these
restriction factors. Therefore, inhibition of these
miRNAs could enhance the basal expression of the
restriction factors in susceptible cells, potentially
decreasing their susceptibility to productive HIV-1
infection.
For a number of years, several drugs such as
prostratin (a plant-based protein kinase C activator)
and other phorbols have been used to activate cellular
transcription factors that lead to the initiation of HIV-1
transcription from latent pro-viruses [208–212]. In
addition, multiple histone deacetylase (HDAC) inhib-
itors have been tested as re-activators of latent
reservoirs [213,214]. The concept behind the usage
of these drugs is to re-activate latent reservoirs (i.e., to
restore viral protein production and new virion
generation) and, subsequently, to use cART that will
inhibit the re-awakened virus preventing the estab-
lishment of new viral reservoirs. This “reactivate and
purge” strategy has been met with definite success in
recent clinical trials; however, the long-term effects
and safety profiles of using HDAC inhibitors have not
been well characterized [215–217]. Since a role for
cellular anti-HIV-1 miRNAs (miR-28, miR-125b,
miR-150, miR-223 and miR-382) in imparting a
transcriptional block to HIV-1 in resting CD4+ T cells
has been reported, it might be worth exploring the
potential utility of a combinatorial inhibition of these
miRNAs that directly target the viralmRNA. Therefore,
if successful, this strategy could be a complementary
approach to the use of HDAC inhibitors or protein
kinase C activators that are not specific to HIV-1
transcriptional regulation, perhaps providing a safer,
potent option in combination with cART.
From a therapeutic standpoint, the use of RNAi
strategies to inhibit HIV-1 infection is already been
explored. Both miRNAs and short hairpin RNAs
(shRNAs) targeting fully complementary and partial-
ly complementary sequences on the HIV-1 genome
have been shown to successfully inhibit HIV-1 in
in vitro experiments [218], with miRNAs being more
efficient in suppressing imperfect targets, which may
be important in the context of a viral genome that is
prone to generate escape mutants. However, several
miRNA-based strategies have been shown to be more
advantageous than siRNA- or shRNA-based anti-
HIV-1 strategies. Thus, the use of polycistronic
miRNA constructs expressing multiple HIV-1 genome
targeting siRNAs or miRNAs [219] or constructs that
express multiple HIV-1 targeting siRNAs in combina-
tion with nucleolar RNAs [220,221] has been shown to
be more efficacious than individual anti-HIV-1 siRNAs
or shRNAs and could be a promising therapeutic
approach.
As potent as the idea of manipulating cellular
miRNAs seem, extreme caution needs to be employed
1191Review: MicroRNAs and HIV-1 Infectionto understand the short-term and long-term potential
side effects. Since miRNAs play crucial roles in
specific, time-dependent and tightly regulated expres-
sion of host proteins, they are important for mainte-
nance of cellular homeostasis. In addition, each
miRNA has the potential to modulate the expression
of multiple targets, potentially complicating even more
the safety of their use. However, there is a prominent
example ofmodulating cellularmiRNAs to control virus
replication, as evidenced by miR-122 inhibition for the
treatment of HCV infection. The liver-specific miR-122
is a pro-HCVmiRNA that has been shown to enhance
HCV-RNA stability and translation, resulting in an
overall increase in virus replication [222–229]. There-
fore, a specific antagonist or anti-oligomiR against
miR-122 has been developed and has shown efficient
virus inhibition in vitro, ex vivo and in studies with
animal models [230–232]. Very recently, results from
human clinical trial phase 2a utilizing the anti-miR-122
inhibitor for treating HCV-infected patients showed
potent suppression of HCV viremia, absence of
generation of viral escape mutants and excellent
safety profiles [233]. Although there are some specific
considerations that apply to the miR-122-HCV suc-
cess story, at least to date, that may not apply to HIV-1
and other viral infections, these results are encourag-
ing and provide a promising platform for the potential
development of future miRNA-related therapeutics to
complement cART for the treatment of HIV-1 infection.Conclusions
HIV-1 infection continues to remain an area of
global health burden despite successful cART.
Based on cellular differentiation or activation states,
differential expression of miRNAs seems to alter
susceptibility to productive HIV-1 infection. It has
been shown that some miRNAs can directly target
the viral mRNAs, and indirect inhibition by cellular
miRNAs targeting the mRNAs of HDFs has also
been noted. As an ever-evolving strategy to infect
and persist, HIV-1 seems to down-regulate some of
these cellular miRNAs that have anti-HIV-1 effects.
Although not completely understood, there is evi-
dence suggesting that HIV-1 inhibits the proteins
involved in biogenesis and maturation of cellular
miRNAs, and global expression profiles of miRNAs
seem to be modulated in HIV-1-infected cells and in
patients. It may be conceivable that, in the future,
miRNAs could potentially be used as biomarkers
to estimate or predict disease progression rates
in infected patients, but further studies exploring
miRNA modulation in patient cohorts and greater
consistency in the miRNAs identified will be needed
before this strategy could be implemented. Further
research and more collaborative studies are also
needed to clarify whether functional vmiRNAs are
produced by HIV-1 and whether miRNA modulationcould be an appropriate therapeutic approach to
complement and reinforce cART with the goal of
HIV-1 eradication.Received 8 September 2013;
Received in revised form 3 December 2013;
Accepted 17 December 2013
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